[ad_1]
Westport, CT, Nov. 4, 2021 (GLOBE NEWSWIRE) – BioSig Technologies, Inc. (Nasdaq: BSGM) (“BioSig” or the “Company”), a medical technology company that markets an innovative signal processing platform for signal enhancement Spectrum of EKG and intracardiac signals, announced today that the company is installing a PURE EP ™ system for number evaluation at Methodist Hospital in San Antonio, TX, one of the largest hospitals in the United States of available beds. This 90-day evaluation contract brings the company to up to 15 installed centers. “Texas is one of the three strategic areas we are focusing on in the targeted commercial launch phase, and we are very excited to have another Texas center in our customer base. Methodist Hospital performed over 1,800 cardiac ablations in the past year, and some of our greatest successes have been in similarly high volume centers. We look forward to making our technology available to more physicians in Texas to further advance our clinical and commercial strategies, ”said Kenneth L. Londoner, Chairman and CEO of BioSig Technologies, Inc.
To date, over 71 physicians at 13 clinical sites have completed over 1600 patient cases using the PURE EP ™ system. The company is in a focused commercial rollout of the PURE EP ™ system in Northeast Texas and Florida, and the technology is regularly deployed at some of the leading centers of excellence in the country, including the Mayo Clinic in Rochester, MN, and St David’s Medical Center in Austin, TX.
Clinical data collected with the PURE EP ™ System in a multicenter study at the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Mayo Clinic Jacksonville, and Massachusetts General Hospital were recently published in the Journal of Cardiovascular Electrophysiology and are electronically available with Open Access via the Wiley Online Library. The study results showed a 93% consensus among the blinded reviewers with an overall improvement of 75% in intracardiac signal quality and confidence in the interpretation of PURE EP ™ signals over conventional sources.
One in 18 Americans has an arrhythmia. Atrial fibrillation is the most common type of arrhythmia, affecting over 33 million people worldwide, including over 6 million in the United States. The number of people with atrial fibrillation is projected to reach 8-12 million by 20501. According to the Centers for Disease Control and Prevention (CDC), atrial fibrillation causes more than 750,000 hospitalizations in the US each year, resulting in approximately $ 6 billion in health care spending annually2.
About BioSig Technologies BioSig Technologies is a medical technology company that markets a proprietary biomedical signal processing platform designed to improve signal fidelity and reveal the full spectrum of EKG and intracardiac signals (www.biosig.com).
The company’s first product, the PURE EP ™ system, is a computerized system for acquiring, digitizing, amplifying, filtering, measuring and calculating, displaying, recording and storing electrocardiographic and intracardiac signals for patients who have electrophysiological (EP ) Undergo procedure in an EP laboratory.
Forward-Looking Statements
This press release contains “forward-looking statements”. Such statements may be preceded by the words “intends”, “can”, “will”, “plan”, “expect”, “anticipate”, “project”, “predict”, “estimate”, “aim”, “believe” “,“ Hopes ”,“ potentially ”or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the control of the company and cannot be predicted or quantified, and consequently actual results could differ materially that are expressed or implied in such forward-looking statements. These risks and uncertainties include, without limitation, risks and uncertainties related to (i) the geographic, social, and economic impact of COVID-19 on our ability to run our business and raise capital when needed in the future; (ii) our inability to manufacture our products and product candidates on a commercial scale either by ourselves or in collaboration with third parties; (iii) difficulties in obtaining finance on economically reasonable terms; (iv) changes in the size and nature of our competition; (v) loss of one or more officers or scientists; and (vi) difficulties in obtaining regulatory approval to market our products and product candidates. More detailed information about the company and the risk factors that could affect the realization of any forward-looking statements are included in the company’s filings with the Securities and Exchange Commission (SEC), including the company’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are strongly encouraged to read these documents free of charge on the SEC’s website at http://www.sec.gov. The company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or for any other reason.
1 Top 10 Things You Should Know About Heart Rhythm; Scripps Health.
2 dealing with atrial fibrillation; Lisa Eramom MA, Medical Economics Journal, February 25, 2019, Volume 96, Issue 4
Andrew Ballou BioSig Technologies, Inc. Vice President, Investor Relations 55 Greens Farms Road Westport, CT 06880 aballou@biosigtech.com 203-409-5444, x133
Copyright 2021 GlobeNewswire, Inc.
[ad_2]
https://www.bakersfield.com/ap/news/biosig-expands-its-installation-base-in-texas/article_58fe1706-b356-561d-af64-1ac4b2be0d60.html
